Matthew W. Foehr
CIK: 0001237556
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (30 total)
- Apr 7, 2026OABI
OmniAb, Inc.
Exercise(M)Direct36.5K shares- - Apr 7, 2026OABI
OmniAb, Inc.
Sale(S)Direct19.2K shares at avg. $1.49$29K - Feb 18, 2026OABI
OmniAb, Inc.
Award(A)DirectRestricted Stock Units
156.3K shares- - Feb 18, 2026OABI
OmniAb, Inc.
Exercise(M)Direct58.3K shares- - Feb 18, 2026OABI
OmniAb, Inc.
Award(A)DirectStock Option
1.6M shares- - Feb 18, 2026OABI
OmniAb, Inc.
Sale(S)Direct30.8K shares at avg. $1.71$53K - Feb 17, 2026OABI
OmniAb, Inc.
Sale(S)Direct20.8K shares at avg. $1.70$35K - Feb 16, 2026OABI
OmniAb, Inc.
Exercise(M)Direct36.5K shares- - Jan 2, 2026VKTX
Viking Therapeutics, Inc.
Sale(S)Direct16K shares at avg. $35.11$562K - Jan 2, 2026VKTX
Viking Therapeutics, Inc.
Award(A)Direct3.2K shares- - Jan 2, 2026VKTX
Viking Therapeutics, Inc.
Exercise(M)Direct16K shares at avg. $3.33$53K - Dec 8, 2025OABI
OmniAb, Inc.
Sale(S)Direct13.7K shares at avg. $1.96$27K - Dec 7, 2025OABI
OmniAb, Inc.
Exercise(M)Direct26.6K shares- - Aug 26, 2025OABI
OmniAb, Inc.
Award(A)Direct540.5K shares at avg. $1.85$1000K - Apr 11, 2025VKTX
Viking Therapeutics, Inc.
Exercise(M)Direct20.8K shares at avg. $8.00$166K - Apr 7, 2025OABI
OmniAb, Inc.
Exercise(M)Direct36.5K shares- - Apr 7, 2025OABI
OmniAb, Inc.
Sale(S)Direct19.4K shares at avg. $2.00$39K - Feb 19, 2025OABI
OmniAb, Inc.
Sale(S)Direct19.5K shares at avg. $3.67$72K - Feb 18, 2025OABI
OmniAb, Inc.
Sale(S)Direct14K shares at avg. $3.68$51K - Feb 18, 2025OABI
OmniAb, Inc.
Award(A)DirectRestricted Stock Units
175K shares- - Feb 18, 2025OABI
OmniAb, Inc.
Award(A)DirectStock Option (right to buy)
1.1M shares- - Feb 16, 2025OABI
OmniAb, Inc.
Exercise(M)Direct36.5K shares- - Feb 15, 2025OABI
OmniAb, Inc.
Exercise(M)Direct26.5K shares- - Jan 21, 2025OABI
OmniAb, Inc.
Sale(S)Direct41.8K shares at avg. $3.24$135K - Jan 17, 2025OABI
OmniAb, Inc.
Award(A)Direct77K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Apr 7, 2026 |  OABI OmniAb, Inc. | Exercise(M) | 36,459 | - | $0 | Direct |
| Apr 7, 2026 | OABI OmniAb, Inc. | Sale(S) | 19,244 | $1.49 | $28,674 | Direct |
| Feb 18, 2026 | OABI OmniAb, Inc. | Award(A) Restricted Stock Units | 156,250 | - | - | Direct |
| Feb 18, 2026 | OABI OmniAb, Inc. | Exercise(M) | 58,333 | - | $0 | Direct |
| Feb 18, 2026 | OABI OmniAb, Inc. | Award(A) Stock Option | 1,562,500 | - | - | Direct |
| Feb 18, 2026 | OABI OmniAb, Inc. | Sale(S) | 30,843 | $1.71 | $52,742 | Direct |
| Feb 17, 2026 | OABI OmniAb, Inc. | Sale(S) | 20,754 | $1.70 | $35,282 | Direct |
| Feb 16, 2026 | OABI OmniAb, Inc. | Exercise(M) | 36,458 | - | $0 | Direct |
| Jan 2, 2026 |  VKTX Viking Therapeutics, Inc. | Sale(S) | 16,000 | $35.11 | $561,694 | Direct |
| Jan 2, 2026 | VKTX Viking Therapeutics, Inc. | Award(A) | 3,150 | - | $0 | Direct |
| Jan 2, 2026 | VKTX Viking Therapeutics, Inc. | Exercise(M) | 16,000 | $3.33 | $53,280 | Direct |
| Dec 8, 2025 | OABI OmniAb, Inc. | Sale(S) | 13,666 | $1.96 | $26,785 | Direct |
| Dec 7, 2025 | OABI OmniAb, Inc. | Exercise(M) | 26,554 | - | - | Direct |
| Aug 26, 2025 | OABI OmniAb, Inc. | Award(A) | 540,540 | $1.85 | $999,999 | Direct |
| Apr 11, 2025 | VKTX Viking Therapeutics, Inc. | Exercise(M) | 20,786 | $8.00 | $166,288 | Direct |
| Apr 7, 2025 | OABI OmniAb, Inc. | Exercise(M) | 36,458 | - | - | Direct |
| Apr 7, 2025 | OABI OmniAb, Inc. | Sale(S) | 19,382 | $2.00 | $38,764 | Direct |
| Feb 19, 2025 | OABI OmniAb, Inc. | Sale(S) | 19,522 | $3.67 | $71,646 | Direct |
| Feb 18, 2025 | OABI OmniAb, Inc. | Sale(S) | 13,964 | $3.68 | $51,388 | Direct |
| Feb 18, 2025 | OABI OmniAb, Inc. | Award(A) Restricted Stock Units | 175,000 | - | - | Direct |
| Feb 18, 2025 | OABI OmniAb, Inc. | Award(A) Stock Option (right to buy) | 1,050,000 | - | - | Direct |
| Feb 16, 2025 | OABI OmniAb, Inc. | Exercise(M) | 36,458 | - | - | Direct |
| Feb 15, 2025 | OABI OmniAb, Inc. | Exercise(M) | 26,549 | - | - | Direct |
| Jan 21, 2025 | OABI OmniAb, Inc. | Sale(S) | 41,811 | $3.24 | $135,468 | Direct |
| Jan 17, 2025 | OABI OmniAb, Inc. | Award(A) | 77,003 | - | $0 | Direct |
1-25 of 30 transactions
About FOEHR MATTHEW W
FOEHR MATTHEW W (SEC CIK 0001237556) files insider reports with the SEC as President and CEO of OmniAb, Inc. (OABI) and Director of Viking Therapeutics, Inc. (VKTX).
Signal8 holds 13 ownership filings by FOEHR MATTHEW W, all Form 4s, filed between Nov 26, 2024 and Apr 7, 2026. Those filings report 30 transactions, from Nov 25, 2024 to Apr 7, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on FOEHR MATTHEW W's filings is in EMERYVILLE, CA.
Recent filings by FOEHR MATTHEW W
- Apr 7, 2026: Option exercise of OABI shares (Form 4, code M).
- Apr 7, 2026: Open-market sale of OABI shares (Form 4, code S).
- Feb 18, 2026: Grant or award of OABI derivative securities (Form 4, code A).
- Feb 18, 2026: Option exercise of OABI shares (Form 4, code M).
- Feb 18, 2026: Grant or award of OABI derivative securities (Form 4, code A).
Other insiders filing for OmniAb, Inc. (OABI)
- Love Steven, Director
- Nwachuku Amechi Ekeke, Chief Operating Officer
- Bertozzi Carolyn R, Director
- Cochran Jennifer R., Director
- Crouse Steven C., Director
- Gotwals Philip J, Director